表紙
市場調查報告書

疫苗的銷售額分析 (2018-2028年):兒童用、成人用、老年人用疫苗、出國者用疫苗、治療疫苗

Global Vaccines Sales Market Forecast 2019-2029: Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra

出版商 Visiongain Ltd 商品編碼 357614
出版日期 內容資訊 英文 201 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
疫苗的銷售額分析 (2018-2028年):兒童用、成人用、老年人用疫苗、出國者用疫苗、治療疫苗 Global Vaccines Sales Market Forecast 2019-2029: Paediatric Vaccines, Adult Vaccines, Elderly Vaccines, Travel Vaccines, Therapeutic Vaccines, Prevnar, Gardasil, Fluzone, Pentacel, ProQuad, Infanrix/Pediarix, Zostavax, RotaTeq, Menactra
出版日期: 2019年06月25日內容資訊: 英文 201 Pages
簡介

本報告提供全球疫苗市場相關調查,人疫苗概要、目的、技術、對象者區分,主要企業相關團體,市場規模 (收益規模)的變化與預測,各主要疫苗、接種對象者及目的、主要已開發國家/新興國家的詳細分析,主要製造商的配合措施,研發產品線趨勢,定性分析等彙整資料。

第1章 調查概要

第2章 全球人疫苗市場:簡介

  • 人疫苗:全世界的疾病預防的追求
  • 社會負擔和經濟負擔
  • 疫苗技術
    • 不活化疫苗
    • 減毒活病毒疫苗
    • 共軛疫苗
    • 重組載體疫苗
  • 人疫苗市場相關企業、團體
    • 政府、國際組織
      • WHO
      • 政府的影響
    • 主要製造商
      • Merck & Co.
      • Sanofi
      • GlaxoSmithKline
      • Pfizer
  • 疫苗區分
    • 兒童用疫苗
    • 成人用疫苗
    • 老年人用疫苗
    • 出國者用疫苗
    • 治療疫苗

第3章 全球疫苗市場展望

  • 全球市場現況
  • 全球市場的預測
  • 產業趨勢、預測

第4章 全球疫苗市場預測:各種類

  • 兒童用疫苗
    • 市場預測
    • 市場趨勢
  • 成人用疫苗
    • 市場預測
    • 市場趨勢
  • 老年人用疫苗
    • 市場預測
    • 市場趨勢
  • 出國者用疫苗
    • 市場預測
    • 市場趨勢
  • 治療疫苗
    • 市場趨勢

第5章 主要疫苗的收益預測

  • Prevnar:肺炎球菌性肺炎
  • Gardasil:HPV
  • Fluzone:流感
  • Pentacel:DtaP、脊髓灰質炎、HiB
  • ProQuad / M-M-R II / Varivax:水痘、麻疹、腮腺炎感冒、德國麻疹
  • Infanrix/Pediarix:白喉、破傷風、無細胞百日咳
  • Zostavax:帶狀皰疹
  • RotaTeq:輪狀病毒
  • GSK Hepatitis Franchise:A型、B型肝炎
  • Menactra:腦膜炎

第6章 主要先進國家市場的預測

  • 美國
    • 市場成果
    • 市場預測
  • 日本
    • 市場成果
    • 市場預測
    • 疫苗差距的應對
  • 歐盟5國
    • 市場成果
    • 市場預測
  • 英國
    • 市場成果
    • 市場預測
  • 法國
    • 市場成果
    • 市場預測
    • 法國的醫療制度:疫苗接種政策
  • 德國
    • 市場成果
    • 市場預測
  • 義大利
    • 市場成果
    • 市場預測
    • 公共醫療方面課題
  • 西班牙
    • 市場成果
    • 市場預測
    • 各地區控制:經濟課題

第7章 主要新興國家市場預測

  • 中國
    • 市場成果
    • 市場預測
    • 國內疫苗產業的建立
  • 印度
    • 市場成果
    • 市場預測
    • 疫苗市場發展的範圍
  • 巴西
    • 市場成果
    • 市場預測
    • 茲卡熱的流行
  • 俄羅斯
    • 市場成果
    • 市場預測
    • 聯邦國家力

第8章 人體疫苗的主要製造商

  • GlaxoSmithKline (GSK)
  • Merck & Co.
  • Sanofi
  • Pfizer
  • Johnson & Johnson
  • AstraZeneca
  • 其他

第9章 R&D現況

  • 預防疫苗的研發產品線
    • 兒童用
    • 成人用
    • 老年人用
    • 出國者用
  • 治療疫苗的研發產品線

第10章 定性分析

  • SWOT分析
  • STEP分析

第11章 總論

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: PHA0453

The global vaccines market is estimated at $41bn in 2018 and is expected to grow at a CAGR of 10.9% during the forecast period. The Paediatric Vaccines segment held 56% of the Global Vaccines market in 2018.

How this report will benefit you

Read on to discover how you can exploit the future business opportunities emerging in this sector.

In this brand new 201-page report you will receive 121 charts - all unavailable elsewhere.

The 201-page report provides clear detailed insight into the global vaccines sales market. Discover the key drivers and challenges affecting the market.

By ordering and reading our brand-new report today you stay better informed and ready to act.

Report Scope

  • Global Vaccines Sales Market forecasts from 2019-2029
  • Global Vaccines Sales Market forecasts from 2019-2029 by Submarket :
  • Paediatric Vaccines
  • Adult Vaccines
  • Elderly Vaccines
  • Travel Vaccines
  • Therapeutic Vaccines

image1

  • Global Vaccines Sales Market forecasts from 2019-2029 by Leading Vaccines:
  • Prevnar
  • Gardasil
  • Fluzone
  • Pentacel
  • ProQuad
  • Infanrix/Pediarix
  • Zostavax
  • RotaTeq
  • Hepatitis Vaccines
  • Menactra
  • Global Vaccines Sales Market forecasts from 2019-2029 by Regional and National Market:
  • US
  • EU5: Germany, France, Italy, UK, Spain
  • Japan
  • Brazil
  • Russia
  • India
  • China
  • Profiles of the selected leading companies:
  • AstraZeneca
  • Eli Lilly
  • Emergent BioSolutions Inc.
  • GlaxoSmithKline
  • Johnson & Johnson
  • Merck & Co.
  • Pfizer
  • Sanofi
  • Serum Indian Institute Pvt. Ltd.
  • Takeda
  • The Vaccines Market Pipeline Analysis
  • A SWOT and STEP analysis of the global vaccines market
  • Key Questions Answered by this Report:
  • What is the current size of the overall global human vaccines market? How much will this market be worth from 2018 to 2029?
  • What are the main drivers and restraints that will shape the overall vaccines market over the next ten years?
  • What are the main segments within the overall human vaccines market? How much will each of these segments be worth for the period 2018 to 2029? How will the composition of the market change during that time, and why?
  • What factors will affect that industry and market over the next ten years?
  • What are the largest national markets for the world vaccines? What is their current status and how will they develop over the next ten years? What are their revenue potentials to 2028?
  • How will political and regulatory forces influence regional markets?
  • How will market shares of the leading national markets change by 2029, and which geographical region will lead the market in 2029?
  • Who are the leading companies and what are their activities, results, developments and prospects?
  • What are the leading vaccines? What are their revenues and latest developments?
  • What are some of the most prominent human vaccines currently in development?
  • What are the main trends that will affect the world vaccines market between 2018 and 2029?
  • What are the main strengths, weaknesses, opportunities and threats for the market?
  • What are the social, technological, economic and political influences that will shape that industry over the next ten years?
  • How will the global vaccines market evolve over the forecasted period, 2018 to 2029?
  • How will the market shares for each checkpoint inhibitor anti-cancer treatment submarket develop from 2018 to 2029?
  • Which therapies can succeed and what revenues could they generate to 2029?
  • What will be the main commercial drivers for the market from 2018 to 2029?
  • How will market shares of prominent national markets change from 2018, and which countries will lead the market in 2029, achieving highest revenues and fastest growth?
  • How will that industry evolve between 2018 and 2029, especially in R&D?

Table of Contents

1. Report Overview

  • 1.1 Overview of the World Vaccines Market
  • 1.2 Why You Should Read This Report
  • 1.3 How This Report Delivers
  • 1.4 Main Questions Answered by This Analytical Study
  • 1.5 Who is This Report For?
  • 1.6 Methods of Research and Analysis
  • 1.7 Frequently Asked Questions (FAQ)
  • 1.8 Associated Visiongain Reports
  • 1.9 About Visiongain

2. Introduction to the World Human Vaccines Market

  • 2.1 Human Vaccines - Aiming for Global Disease Prevention
  • 2.2 What is the Social and Economic Burden?
  • 2.3 Vaccine Technology
    • 2.3.1 Inactivated Vaccines
    • 2.3.2 Live Attenuated Vaccines
    • 2.3.3 Conjugate Vaccines
    • 2.3.4 Recombinant Vector Vaccines
  • 2.4 Key Influencers of the Human Vaccine Market
    • 2.4.1 Governments and International Organizations
      • 2.4.1.1 The World Health Organisation (WHO)
      • 2.4.1.2 The Governmental Influence
    • 2.4.2 Leading Manufacturers
      • 2.4.2.1 Merck& Co.
      • 2.4.2.2 Sanofi
      • 2.4.2.3 GlaxoSmithKline
      • 2.4.2.4 Pfizer
  • 2.5 Human World Vaccines - Market Segmentation
    • 2.5.1 Paediatric Vaccines
    • 2.5.2 Adult Vaccines
    • 2.5.3 Elderly Vaccines
    • 2.5.4 Travel Vaccines
    • 2.5.5 Therapeutic Vaccines

3. World Vaccine Market Outlook, 2019-2029

  • 3.1 World Vaccine Market, 2018
    • 3.1.1 Paediatric Vaccines Maintains Constant Demand
    • 3.1.2 Ageing Population Requires More Care
    • 3.1.3 Emerging Markets Demand Better Immunity
  • 3.2 The World Human Vaccines Forecast, 2019-2029
  • 3.3 The World Vaccine Market: Industry Trends
    • 3.3.1 Undulating Demand
    • 3.3.2 Supply Restraints
    • 3.3.3 Funding Trends
    • 3.3.4 Protecting the Workforce of an Economy

4. World Vaccine Submarkets: Prospects, 2019-2029

  • 4.1 Paediatric Vaccines
    • 4.1.1 Paediatric Vaccine Forecast, 2019-2029
    • 4.1.2 Paediatric Vaccine Trends
      • 4.1.2.1 Innovative Delivery
      • 4.1.2.2 Fear Factor
      • 4.1.2.3 Novel Vectors
  • 4.2 Adult Vaccines
    • 4.2.1 Adult Vaccine Forecast, 2019-2029
    • 4.2.2 Adult Vaccine Trends
      • 4.2.2.1 Fighting the Flu
      • 4.2.2.2 HPV
      • 4.2.2.3 Repeat Doses for Continued Protection
  • 4.3 Elderly Vaccines
    • 4.3.1 Elderly Vaccine Forecast, 2019-2029
    • 4.3.2 Elderly Vaccine Trends
      • 4.3.2.1 With Age Comes Greater Risk
      • 4.3.2.2 Ageing Population across the Globe
  • 4.4 Travel Vaccines
    • 4.4.1 Travel Vaccines Forecast, 2018-2029
    • 4.4.2 Travel Vaccine Trends
      • 4.4.2.1 Zika Virus Outbreak
      • 4.4.2.2 Globalization Carries Diseases
  • 4.5 Therapeutic Vaccines
    • 4.5.1 Therapeutic Vaccine Trends

5. Leading Vaccines: Revenue Forecasts, 2019-2029

  • 5.1 Prevnar (Pfizer) - Pneumococcal Pneumonia
  • 5.2 Gardasil (Merck & Co.) - HPV
  • 5.3 Fluzone (Sanofi) - Influenza
  • 5.4 Pentacel (Sanofi) - DtaP, Polio, HiB
  • 5.5 ProQuad / M-M-R II / Varivax (Merck and Co.) - Varicella/Chickenpox, Measles, Mumps, Rubella.
  • 5.6 Infanrix/Pediarix (GSK) - Diptheria, Tetanus and Acellular Pertussis
  • 5.7 Zostavax (Merck and Co.) - Herpes
  • 5.8 RotaTeq (Merck and Co.) - Rotavirus
  • 5.9 Hepatitis Vaccines (GSK) - Hepatitis A & B
  • 5.10 Menactra (Sanofi) - Meningococcal

6. Regional and Leading Developed National Vaccines Markets, 2019-2029

  • 6.1 North America Vaccine Market, 2019-2029
    • 6.1.1 The US Vaccine Market, 2018
    • 6.1.2 The US Vaccine Market Forecast, 2019-2029
  • 6.2 Japanese Vaccine Market, 2019-2029
    • 6.2.1 The Japanese Vaccine Market, 2018
    • 6.2.2 The Japanese Vaccine Market Forecast, 2019-2029
    • 6.2.3 Addressing the Alleged Vaccine Gap
  • 6.3 EU5 Vaccine Market, 2019-2029
    • 6.3.1 The EU5 Vaccine Market, 2018
    • 6.3.2 The EU5 Vaccine Market Forecast, 2019-2029
  • 6.4 United Kingdom Vaccine Market, 2019-2029
    • 6.4.1 The UK Vaccine Market, 2018
    • 6.4.2 The UK Vaccine Market Forecast, 2019-2029
  • 6.5 France: Vaccine Market, 2019-2029
    • 6.5.1 The French Vaccine Market, 2018
    • 6.5.2 The French Vaccine Market Forecast, 2019-2029
    • 6.5.3 French Healthcare System - Immunization Policy
  • 6.6 Germany: Vaccine Market, 2019-2029
    • 6.6.1 The German Vaccine Market, 2018
    • 6.6.2 The German Vaccine Market Forecast, 2019-2029
  • 6.7 Italy: Vaccine Market, 2019-2029
    • 6.7.1 The Italian Vaccine Market, 2018
    • 6.7.2 The Italian Vaccine Market Forecast, 2019-2029
    • 6.7.3 Challenges in Public Healthcare
  • 6.8 Spain: Vaccine Market, 2019-2029
    • 6.8.1 The Spanish Vaccine Market, 2018
    • 6.8.2 The Spanish Vaccine Market Forecast, 2019-2029
    • 6.8.3 District Rules - Economic Challenges

7. Leading Emerging National Markets, 2019-2029

  • 7.1 China: Vaccine Market, 2019-2029
    • 7.1.1 The Chinese Vaccine Market, 2018
    • 7.1.2 The Chinese Vaccine Market Forecast, 2019-2029
    • 7.1.3 Setting-Up Domestic Vaccine Industries
  • 7.2 India: Vaccine Market, 2019-2029
    • 7.2.1 The Indian Vaccine Market, 2018
    • 7.2.2 The Indian Vaccine Market Forecast, 2019-2029
    • 7.2.3 The Extent to which the Vaccine Market Can Flourish?
  • 7.3 Brazil: Vaccine Market, 2019-2029
    • 7.3.1 The Brazilian Vaccine Market, 2018
    • 7.3.2 The Brazilian Vaccine Market Forecast, 2019-2029
    • 7.3.3 Zika Outbreak
  • 7.4 Russia: Vaccine Market, 2019-2029
    • 7.4.1 The Russian Vaccine Market, 2018
    • 7.4.2 The Russian Vaccine Market Forecast, 2019-2029
    • 7.4.3 Power of the State

8. Leading Manufacturers of Vaccines for Human Use

  • 8.1 GlaxoSmithKline (GSK)
    • 8.1.1 GSK Vaccine Performance
    • 8.1.2 GSK Developments
      • 8.1.2.1 Mergers and Acquisitions
      • 8.1.2.2 GSK Vaccine Pipeline
    • 8.2 Merck& Co.
    • 8.2.1 Merck Vaccine Performance
    • 8.2.2 Merck Developments
      • 8.2.2.1 Merck Market Movements
      • 8.2.2.2 Collaborations
      • 8.2.2.3 Merck Pipeline
    • 8.3 Sanofi
    • 8.3.1 Sanofi Vaccine Performance
    • 8.3.2 Sanofi Developments
      • 8.3.2.1 Acquisitions & Expansions
      • 8.3.2.2 Sanofi Vaccine Pipeline
    • 8.4 Pfizer
    • 8.4.1 Pfizer Vaccine Performance
      • 8.4.1.1 Financial Overview
    • 8.4.2 Pfizer Developments
      • 8.4.2.1 Pfizer Mergers & Acquisitions
      • 8.4.2.2 Pfizer Pipeline
  • 8.5 Johnson & Johnson
    • 8.5.1 Financial Overview
  • 8.6 AstraZeneca
    • 8.6.1 Financial Overview
  • 8.7 Eli Lilly and Company
    • 8.7.1 Eli Lilly and Company Vaccine Performance
    • 8.7.1.1 Financial Overview
    • 8.7.2 Eli Lilly and Company Developments
  • 8.8 Takeda Pharmaceutical Company Limited
    • 8.8.1 Takeda Pharmaceutical Company Limited Vaccine Performance
      • 8.8.1.1 Financial Overview
  • 8.9 Serum Institute of India Private Limited
    • 8.9.1 Serum Institute of India Private Limited Vaccine Performance
  • 8.10 Emergent BioSolutions Inc.
    • 8.10.1 Emergent BioSolutions Inc. Vaccine Performance
  • 8.11 Key Strategic Acquisitions and Collaborations
  • 8.12 Other Companies Serving the Vaccines Market

9. Research & Development, 2018

  • 9.1 Prophylactic Vaccines R&D Pipeline
    • 9.1.1 Paediatric Vaccines R&D Pipeline
    • 9.1.2 Adult Vaccines R&D Pipeline
    • 9.1.3 Elderly Vaccines R&D Pipeline
    • 9.1.4 Travel Vaccines R&D Pipeline
  • 9.2 Therapeutic Vaccines R&D Pipeline

10. Qualitative Analysis of the World Vaccines Market

  • 10.1 SWOT Analysis of the World Human Vaccines Market
    • 10.1.1 Strengths
      • 10.1.1.1 Ageing Population
      • 10.1.1.2 Prevention is Better than Cure
      • 10.1.1.3 Demand from Emerging Markets Continue
      • 10.1.1.4 Promising R&D Pipeline
      • 10.1.1.5 Increasing Awareness
    • 10.1.2 Weaknesses
      • 10.1.2.1 High Manufacturing Costs
      • 10.1.2.2 Time Constraints
      • 10.1.2.3 Barriers to Market Entry
    • 10.1.3 Opportunities
      • 10.1.3.1 Constant Improvements in Vaccine Technology and Delivery Methods
      • 10.1.3.2 Shifting Focus on Adults Vaccines
    • 10.1.4 Threats
      • 10.1.4.1 Oligarchic Presence of Pharmaceutical Giants
      • 10.1.4.2 Productivity Gap
  • 10.2 STEP Analysis of the World Human Vaccines Industry and Market
    • 10.2.1 Social Factors
      • 10.2.1.1 Maintaining a Healthier Workforce
      • 10.2.1.2 Public Hesitation - Fear of Unwanted Side-Effects
    • 10.2.2 Technological Forces
      • 10.2.2.1 Evolution of Vaccine Technology Pave the Way for Prophylactics and Therapeutics
    • 10.2.3 Economic Factors
      • 10.2.3.1 High Costs of Production
      • 10.2.3.2 Soaring Vaccines Demand from Developing Countries
    • 10.2.4 Political Factors
      • 10.2.4.1 Governments Play Crucial Roles in Vaccination

11. Conclusions

  • 11.1 Segment Market Share Shift
  • 11.2 Elderly People Become the New Target Market
  • 11.3 Endemic Infections Drive Travel Vaccines Growth
  • 11.4 Emerging Markets: High Demand for Vaccines
  • 11.5 Demand in Mature Pharma Markets Continues: in Particular Japan Will Show Sales Growth
  • 11.6 Strong and Diverse Research and Development
  • 11.7 Concluding Remarks

Appendices

  • Associated Visiongain Reports
  • Visiongain Report Sales Order Form
  • About Visiongain
  • Visiongain Report Evaluation Form

List of Tables

  • Table 3.1 The Global Vaccines Market: Revenue Forecast ($bn), Annual Growth (%), CAGRs (%), 2019-2029
  • Table 4.1 World Vaccines Submarkets: Revenue Forecasts ($bn), AGR (%), CAGR (%), 2019-2029
  • Table 4.2 World Vaccines Submarkets: Market Shares (%), 2017-2029
  • Table 4.3 World Paediatric Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 4.4 World Adult Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 4.5 World Elderly Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 4.6 World Travel Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 5.1 Prevnar Revenue ($bn), 2014-2017
  • Table 5.2 Prevnar Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 5.3 Gardasil Revenue ($bn), 2014-2017
  • Table 5.4 Gardasil Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 5.5 Fluzone/Vaxigrip: Revenue ($bn), 2014-2017
  • Table 5.6 Fluzone Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 5.7 Pentacel Revenue ($bn), 2014-2017
  • Table 5.8 Pentacel Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 5.9 ProQuad / M-M-R II / Varivax Revenue ($bn), 2014-2017
  • Table 5.10 ProQuad / M-M-R II / Varivax Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 5.11 Infanrix/Pediarix Revenue ($bn), 2014-2016
  • Table 5.12 Infanrix/Pediarix Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 5.13 Zostavax Revenue ($bn), 2014-2017
  • Table 5.14 Zostavax Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 5.15 RotaTeq Revenue ($bn), 2014-2017
  • Table 5.16 RotaTeq Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 5.17 GSK Hepatitis Vaccines Revenue ($bn), 2014-2016
  • Table 5.18 GSK Hepatitis Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2018-2029
  • Table 5.19 Menactra Revenue ($bn), 2014-2017
  • Table 5.20 Menactra Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2018-2029
  • Table 6.1 Leading National Market Revenue Forecasts ($bn), 2018, 2023, 2029
  • Table 6.2 Leading Developed National Markets Revenue Forecasts ($bn), 2018, 2023, 2029
  • Table 6.3 Leading Developed National Market Shares (%), 2018, 2023, 2029
  • Table 6.4 North America Vaccines Revenue Forecast by Submarket ($bn), Annual Growth (%) and CAGR (%), 2019-2029
  • Table 6.5 North America Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029
  • Table 6.6 The US Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029
  • Table 6.7 The Japanese Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 6.8 Europe Vaccines Revenue Forecast by Submarkets ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 6.9 Europe Vaccines Revenue Forecast by Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2019-2029
  • Table 6.10 The EU5 Vaccines World Market Shares (%), 2018, 2023, 2029
  • Table 6.11 EU5 Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 6.12 The UK Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 6.13 The French Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 6.14 The German Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 6.15 The Italian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 6.16 The Spanish Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 7.1 Asia-Pacific Vaccines Revenue Forecast by Submarket ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 7.2 Asia-Pacific Vaccines Revenue Forecast, By Leading Vaccines ($bn), Annual Growth (%) and CAGR (%), 2018-2029
  • Table 7.3 Leading Emerging National Market Revenue Forecasts ($bn), 2018, 2023, 2029
  • Table 7.4 Leading Emerging National Market Shares (%), 2018, 2023, 2029
  • Table 7.5 The Chinese Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%), and CAGR (%), 2019-2029
  • Table 7.6 The Indian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029
  • Table 7.7 The Brazilian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share (%) and CAGR (%), 2019-2029
  • Table 7.8 The Russian Vaccines Revenue Forecast ($bn), Annual Growth (%), Market Share and CAGR (%), 2019-2029
  • Table 9.1 Prophylactic Vaccines in Development, 2018
  • Table 9.2 Paediatric Vaccines in Development, 2018
  • Table 9.3 Adult Vaccines in Development, 2018
  • Table 9.4 Elderly Vaccines in Development, 2018
  • Table 9.5 Travel Vaccines in Development, 2018
  • Table 9.6 Therapeutic Vaccines in Development, 2018

List of Figures

  • Figure 1.1 World Vaccines Market Segmentation, 2017
  • Figure 3.1 Vaccines Market Share within Global Pharmaceutical Market (%), 2018
  • Figure 3.2 World Vaccines Leading National Market Shares (%), 2018
  • Figure 3.3 World Vaccines Leading National Market Shares (%), 2023
  • Figure 3.4 World Vaccines Leading National Market Shares (%), 2029
  • Figure 3.5 World Vaccines Market: Drivers and Restraints
  • Figure 4.1 World Vaccines Submarket (%) Segmentation, 2018
  • Figure 4.2 World Paediatric Vaccines Market Share (%), 2019
  • Figure 4.3 World Paediatric Vaccines Market Share (%), 2023
  • Figure 4.4 World Paediatric Vaccines Market Share (%), 2029
  • Figure 4.5 World Paediatric Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 4.6 World Adult Vaccines Market Share (%), 2019
  • Figure 4.7 World Adult Vaccines Market Share (%), 2023
  • Figure 4.8 World Adult Vaccines Market Share (%), 2029
  • Figure 4.9 World Adult Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 4.10 World Elderly Vaccines Market Share (%), 2019
  • Figure 4.11 World Elderly Vaccines Market Share (%), 2023
  • Figure 4.12 World Elderly Vaccines Market Share (%), 2029
  • Figure 4.13 World Elderly Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 4.14 World Travel Vaccines Market Share (%), 2019
  • Figure 4.15 World Travel Vaccines Market Share (%), 2023
  • Figure 4.16 World Travel Vaccines Market Share (%), 2029
  • Figure 4.17 World Travel Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 5.1 Prevnar Revenue Forecast ($bn), 2019-2029
  • Figure 5.2 Gardasil Revenue Forecast ($bn), 2019-2029
  • Figure 5.3 Fluzone Revenue Forecast ($bn), 2019-2029
  • Figure 5.4 Pentacel Revenue Forecast ($bn), 2019-2029
  • Figure 5.5 ProQuad / M-M-R II / VarivaxRevenue Forecast ($bn), 2019-2029
  • Figure 5.6 Infanrix/Pediarix Revenue Forecast ($bn), 2019-2029
  • Figure 5.7 Zostavax Revenue Forecast ($bn), 2019-2029
  • Figure 5.8 RotaTeq Revenue Forecast ($bn), 2019-2029
  • Figure 5.9 GSK Hepatitis Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 5.10 Menactra Revenue Forecast ($bn), 2019-2029
  • Figure 6.1 The US Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 6.2 The Japanese Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 6.3 EU5 Vaccines Market Share (%), 2018
  • Figure 6.4 EU5 Vaccines Market Share (%), 2023
  • Figure 6.5 EU5 Vaccines Market Share (%), 2029
  • Figure 6.6 The UK Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 6.7 The French Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 6.8 The German Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 6.9 The Italian Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 6.10 The Spanish Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 7.1 BRIC Countries Vaccines Market Share (%), 2018
  • Figure 7.2 BRIC Countries: Vaccines Market Share (%), 2023
  • Figure 7.3 BRIC Countries: Vaccines Market Share (%), 2029
  • Figure 7.4 The Chinese Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 7.5 The Indian Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 7.6 The Brazilian Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 7.7 The Russian Vaccines Revenue Forecast ($bn), 2019-2029
  • Figure 8.1 GSK Vaccines Revenue ($bn), 2015-2017
  • Figure 8.2 GSK Vaccines Region Breakdown (%), 2017
  • Figure 8.3 Merck Vaccines Revenue (%), 2017
  • Figure 8.4 Sanofi Vaccines Revenue ($bn), 2014-2017
  • Figure 8.5 Pfizer Revenue ($bn), 2014-2017
  • Figure 8.6 J&J Revenue ($bn), 2014-2017
  • Figure 8.7 AstraZeneca Revenue ($bn), 2014-2017
  • Figure 8.8 Eli Lilly and Company Revenue ($bn), 2014-2017
  • Figure 8.9 Takeda Pharmaceutical Revenue ($bn), 2014-2017
  • Figure 10.1 SWOT Analysis of the World Vaccines Market
  • Figure 10.2 STEP Analysis of the World Vaccines Market
  • Figure 11.1 World Paediatric Vaccines Revenue Forecast ($bn), 2018-2029
  • Figure 11.2 World Elderly Vaccines Revenue Forecast ($bn), 2018-2029
  • Figure 11.3 Asia-Pacific Vaccines Revenue Forecast (% Share), 2018-2029

Companies Listed

  • AstraZeneca
  • Bavarian Nordic
  • Bayer
  • Bharat Immunologicals and Biologicals Corporation Limited (BIBCOL)
  • Binnopharm
  • BiondVax
  • Bristol-Myers Squibb
  • Chemo-Sero-Therapeutic Research Institute
  • China National Biotec Group
  • Denka Seiken
  • Eli Lilly
  • Emergent BioSolutions Inc
  • Fresenius
  • GlaxoSmithKline (GSK)
  • GlaxoWellcome
  • Henogen
  • Immatics
  • InterveXion Therapeutics
  • Johnson & Johnson
  • LigoCyte
  • MedImmune
  • Merck & Co.
  • Merck Sharp & Dohme Corp
  • Nanolek
  • NewLink Genetics
  • Okairos
  • PaxVax
  • Pfizer
  • Protein Science
  • Roche
  • Sanofi Pasteur
  • Serum Indian Institute Pvt. Ltd.
  • SmithKline Beecham
  • Takeda
  • Themis Bioscience

Organizations Mentioned in the Report

  • Centers for Disease Control and Protection (CDC)
  • Centre for Biologics Evaluation and Research (CBER)
  • Developing Countries Vaccine Manufacturers Network (DCVMN)
  • European Medicines Agency (EMA)
  • Federation of Pharmaceutical Manufacturers & Associations (IFPMA)
  • Food and Drug Administration (FDA)
  • Global Alliance for Vaccines
  • Global Alliance for Vaccines and Immunization (GAVI)
  • International Financing Facility for Immunisation
  • National Health Service (NHS)
  • Pan American Health Organization (PAHO)
  • The Butantan Institute
  • The Indian Department of Biotech
  • The Ministry of Health, Labour and Welfare and the Health Service Bureau
  • UNICEF
  • World Health Organization (WHO)
Back to Top